NCT04371185 - Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects | Biotech Hunter

Enrollment

270

Participants

Timeline

Start Date

August 8, 2020

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions

Psoriasis

Interventions

DRUG

BAT2206

45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection

DRUG

Stelara(US-licensed)

45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection

DRUG

Stelara(EU-licensed)

45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection

Trial Locations (1)

The First Hospital of Jilin University, Jilin